ATE420890T1 - Isoleucyl-valyl-threonyl-asparaginyl-threonyl- threonin (ivtntt) enthaltende biologisch wirksame peptide - Google Patents

Isoleucyl-valyl-threonyl-asparaginyl-threonyl- threonin (ivtntt) enthaltende biologisch wirksame peptide

Info

Publication number
ATE420890T1
ATE420890T1 AT04798591T AT04798591T ATE420890T1 AT E420890 T1 ATE420890 T1 AT E420890T1 AT 04798591 T AT04798591 T AT 04798591T AT 04798591 T AT04798591 T AT 04798591T AT E420890 T1 ATE420890 T1 AT E420890T1
Authority
AT
Austria
Prior art keywords
threonyl
isoleucyl
asparaginyl
valyl
threonine
Prior art date
Application number
AT04798591T
Other languages
English (en)
Inventor
Wai Ming Wong
Kong Lam
Original Assignee
Cms Peptides Patent Holding Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cms Peptides Patent Holding Co filed Critical Cms Peptides Patent Holding Co
Application granted granted Critical
Publication of ATE420890T1 publication Critical patent/ATE420890T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04798591T 2003-11-19 2004-11-18 Isoleucyl-valyl-threonyl-asparaginyl-threonyl- threonin (ivtntt) enthaltende biologisch wirksame peptide ATE420890T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52383703P 2003-11-19 2003-11-19

Publications (1)

Publication Number Publication Date
ATE420890T1 true ATE420890T1 (de) 2009-01-15

Family

ID=34632832

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04798591T ATE420890T1 (de) 2003-11-19 2004-11-18 Isoleucyl-valyl-threonyl-asparaginyl-threonyl- threonin (ivtntt) enthaltende biologisch wirksame peptide

Country Status (10)

Country Link
US (1) US7396817B2 (de)
EP (1) EP1689771B1 (de)
JP (1) JP4614966B2 (de)
KR (1) KR101258128B1 (de)
CN (1) CN100434437C (de)
AT (1) ATE420890T1 (de)
DE (1) DE602004019141D1 (de)
ES (1) ES2320899T3 (de)
HK (1) HK1092162A1 (de)
WO (1) WO2005051981A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides

Also Published As

Publication number Publication date
CN1875032A (zh) 2006-12-06
KR20060103508A (ko) 2006-10-02
EP1689771A1 (de) 2006-08-16
JP4614966B2 (ja) 2011-01-19
ES2320899T3 (es) 2009-05-29
EP1689771B1 (de) 2009-01-14
WO2005051981A1 (en) 2005-06-09
US7396817B2 (en) 2008-07-08
DE602004019141D1 (de) 2009-03-05
JP2008500272A (ja) 2008-01-10
US20060234943A1 (en) 2006-10-19
CN100434437C (zh) 2008-11-19
HK1092162A1 (en) 2007-02-02
KR101258128B1 (ko) 2013-05-06

Similar Documents

Publication Publication Date Title
EP1778842B8 (de) Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
DE50004018D1 (de) Verwendung natriuretischer peptide als antibiotisch wirksame substanzen zur behandlung von bakteriellen infektionen
BR0009964A (pt) Peptìdios artificiais com atividade desuperfìcie e sua utilização na preparação de surfactante artificial
WO2003103589A3 (en) USE OF IL-21 IN THE TREATMENT OF CANCER AND OTHER THERAPEUTIC APPLICATIONS
DE60019598D1 (de) Verbindungen zur behandlung von sexuellen funktionsstörungen
KR960703015A (ko) 후천성 면역결핍증 치료용 약물의 제조시 노나- 및 데카펩타이드의 용도(Use of nona-and decapeptides in the preparation of a durg for the treatment of AIDS)
UA72915C2 (uk) Поживна ентеральна композиція, призначена для підтримки зростання та дозрівання недорозвинених шлунково-кишкових трактів у молодих ссавців та її застосування
WO2003028757A1 (fr) Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
TR200103339T2 (tr) Geliştirilmiş çözülürlük özelliklerine sahip yeni LHRH-antagonistleri.
HK1092162A1 (en) Biologically active peptides comprising isoleucyl-valyl-threonyl- asparaginyl-threonyl-threonine (ivtntt)
NZ591827A (en) Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating immune reaction in a radiotherapy-induced immuno-compromised subject
EP1812035A4 (de) Peptid mit antitumoraler wirkung
GB0203419D0 (en) Peptide
GB0203420D0 (en) Peptide
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen
DE50114335D1 (de) Lh-rh-antagonisten, deren herstellung und verwendung als arzneimittel
JP2004533846A5 (de)
MXPA03011190A (es) Peptidos biologicamente activos.
EP1557466A4 (de) Tumorantigenprotein und dessen verwendung
DE60223232D1 (de) Mucinpeptid mit immunstärkenden eigenschaften
PT1105503E (pt) Guanililciclase humana soluvel alfal/betal (hsgc alfal/betal) isolada e purificada
DE60325227D1 (de)
WO2004011638A3 (en) Deoxyuridine 5' triphosphate nucleotidohydrolase polypeptides and structures
MX9604539A (es) Aminoacidos modificados para la distribucion de farmaco.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties